Cita APA

Zong, Y., Peng, Z., Wang, X., Lu, M., Shen, L., & Zhou, J. (2020). Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Manag Res.

Citación estilo Chicago

Zong, Yuan, Zhi Peng, Xicheng Wang, Ming Lu, Lin Shen, y Jun Zhou. "Efficacy and Safety of Nab-Paclitaxel Plus S-1 Versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma." Cancer Manag Res 2020.

Cita MLA

Zong, Yuan, et al. "Efficacy and Safety of Nab-Paclitaxel Plus S-1 Versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma." Cancer Manag Res 2020.